Effects of misoprostol on cisplatin-induced renal damage in rats

Food and Chemical Toxicology

Volumn 49, Issue 7, 2011, Pages 1556-1559

  Ozer, Mehmet Kaya ^a   Asci, Halil ^a   Oncu, Meral ^a   Calapoglu, Mustafa ^b   Savran, Mehtap ^a   Yesilot, Sukriye ^a   Candan, Ibrahim Aydin ^a   Cicek, Ekrem ^a  

^a SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b SULEYMAN DEMIREL UNIVERSITY   (Turkey)

Author keywords

Cisplatin; Misoprostol; Rat; Renal damage

Indexed keywords

CATALASE; MALONALDEHYDE; MISOPROSTOL; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HISTOPATHOLOGY; KIDNEY INJURY; KIDNEY STRUCTURE; LIPID PEROXIDATION; MALE; MICROSCOPY; NONHUMAN; OXIDATIVE STRESS; RAT; RENAL PROTECTION; SIDE EFFECT; TISSUE LEVEL;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; CATALASE; CISPLATIN; CYTOPROTECTION; KIDNEY; KIDNEY DISEASES; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MISOPROSTOL; OXIDATIVE STRESS; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE;

RATTUS;

EID: 79957658290     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2011.03.051     Document Type: Article

References (25)

1. Aebi H. Catalase in vitro. Methods Enzymol. 1984, 105:121-126.
2. Appenroth D., Fröb S., Kersten L., et al. Protective effects of vitamin E and C on cisplatin nephrotoxicity in developing rats. Arch. Toxicol. 1997, 71:677-683.
3. Babu E., Gopalakrishnan V.K., Sriganth I.N., et al. Cisplatin induced nephrotoxicity and the modulating effect of glutathione ester. Mol. Cell. Biochem. 1995, 144:7-11.
4. Baliga R., Zhang Z., Baliga M., et al. In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int. 1998, 53:394-401.
5. Brunton L.L., Lazo J.S., Parker K.L. Goodman and Gilman's the Pharmacologycal Basis of Therapeutics 2006, Mc Graw-Hill Companies, New York.
6. Draper H.H., Hadley M. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol. 1990, 186:421-431.
7. Hafez T., Moussa M., Nesim I., Baligh N., Davidson B., Abdul-Hadi A. The effect of intraportal prostaglandin E1 on adhesion molecule expression, inflammatory modulator function, and Histology in canine hepaticischemia/reperfusioninjury. J. Surg. Res. 2007, 138:88-99.
8. Lau A.H. Apoptosis induced by cisplatin nephrotoxic injury. Kidney Int. 1999, 56:1295-1298.
9. Lim S.P., Andrews F.J., O'Brien P.E. Acetaminophen-induced microvascular injury in the rat liver: protection with MP. Hepatology 1995, 22:1776-1781.
10. Ozbek E., Cekmen M., Turkoz Y. The effects of caffeic acid phenethyl ester on cisplatin nephrotoxicity increased antioxidant enzyme activity in kidney. Int. Med. J. 2000, 7:129-131.
11. Paller M.S., Manivel J.C. Prostaglandins protect kidneys against ischemic and toxic injury by a cellular effect. Kidney Int. 1992, 42(6):1345-1354.
12. Parlakpinar H., Sahna E., Ozer M.K., Ozugurlu F., Vardi N., Acet A. Physiological and pharmacological concentrations of melatonin protect against cisplatin-induced acute renal injury. J. Pineal Res. 2002, 33(3):161-166.
13. Ranchal I., Gonzalez R., Lopez-Sanchez L.M., et al. The differential effect of PGE1 on d-galactosamine-induced nitrosative stress and cell death in primary culture of human hepatocytes. Prostaglandins Other Lipid Mediat. 2006, 79:245-259.
14. Rao M., Kumar M.M., Rao M.A. In vitro and in vivo effects of phenolic antioxidants against cisplatin-induced nephrotoxicity. J. Biochem. 1999, 125(2):383-390.
15. Salam O.M., Saleem A.A., Omara E.A., Hassan N.S. Hepatoprotective effects of MP and silymarin on carbon tetrachloride-induced hepatic damage in rats. Fundam. Clin. Pharmacol. 2009, 23(2):179-188.
16. Sostres C., Gargallo C.J., Arroyo M.T., Lanas A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract. Res. Clin. Gastroenterol. 2010, 24(2):121-132.
17. Sener G., Satiroglu H., Kabasakal L., et al. The protective effect of melatonin on cisplatin nephrotoxicity. Fundam. Clin. Pharmacol. 2000, 14:553-560.
18. Sun Y., Oberley L.W., Li Y. A simple method for clinical assay of superoxide dismutase. Clin. Chem. 1988, 34(3):497-500.
19. Yang H., Majno P., Morel P., et al. Prostaglandin E(1) protects human liver sinusoidal endothelial cell from apoptosis induced by hypoxia reoxygenation. Microvasc. Res. 2002, 64:94-103.
20. Yang D.Z., Wang A.H.J. Structural studies of interactions between anticancer platinum drugs and DNA. Prog. Biophys. Mol. Biol. 1997, 66:81-111.
21. Yin H., Cheng L., Langenbach R., Ju C. Prostaglandin I(2) and E(2) mediate the protective effects of cyclooxygenase-2 in a mouse model of immune-mediated liver injury. Hepatology 2007, 45:159-169.
22. Watanabe H., Kanno H. Experim ental studies of the effect of deferoxamine mesilate on cisplatin induced toxicity. Nippon Jibiinkoka Gakkai Kaiho 1998, 101:967-978.
23. Walker E.M., Gale G.R. Methods of reduction of cisplatin nephrotoxicity. Ann. Clin. Lab. Sci. 1981, 11:397-410.
24. Winston J.A., Safirstein R. Reduce d renal blood flow in early cisplatin-induced acute renal failure in the rat. Am. J. Physiol. 1985, 249:490-496.
25. Zunino F., Pratesi G., Micheloni A., et al. Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug. Chem. Biol. Interact. 1989, 70:89-101.